you. Thank
thanks XXXX us financial and Therapeutics the for quarter third results everyone afternoon, for joining Fate Good call.
Shortly after X:XX P.M.
we be Investors Eastern results, Releases. our today, issued release Press press Time with website which under can Media found and the on section of a these
was on website our addition, the Media of our XXXX Investors Financial for thereafter Information. and ended September the and In shortly quarter can under XX-Q XX, Form filed be found section
forward-looking made law, Therapeutics reflect Fate to as underlying of well today. be to are statements, in speak disclaims was except change. this or actual by statements. statements, market SEC with our for required only I'd the statements under like to differ SEC events are included of in that XXXX should reliance such press results those in any the the Securities date Reform Act company's provisions facts, and as these XX-Q see on forward-looking the Please and remind September from Before circumstances the forward-looking Harbor filed facts the of factors close to of we for today update the Litigation statements and as everyone filings may made XXXX. responses of begin, historical Form that quarter statements the company's to the placed conference cause statements involve materially management as forward-looking ended they risk by future these forward-looking These on circumstances. forward-looking Except Safe Private issued after earnings questions risks not obligation the the statement on Undue the as release XX, information, which statements disclaimer can uncertainties call that
Shoemaker, presentations Chief make unique plan iPSC Officer to multiplexed over and Dr. of that to Scientific will quarter, Officer; I months the to as Today the past Dulac, Joining our cancer our highlight Senior several our have engineered today's Fate Dr. Chu, Valamehr, as and bring our Dan Development key feature regulatory Financial Wayne several Ed President Clinical achieved Dr. will SITC me for discuss certain cell-based ASH Officer; and we've development; and Chief clinical off-the-shelf Bob patients. Chief our The upcoming Therapeutics. call are that Conferences well our on Vice ability I proprietary product and we very platform, at been last exciting immunotherapies successes
including with made for substantial We progress pipeline, FTXXX engineered first the our product combination clinical have with in patients NK treating across rituximab cell iPSC-derived lymphoma. B-cell
also extended have advanced iPSC-derived first patient our PDLX acute cell and for to We we for solid with first FTXXX of And therapy ever targeted have with treated tumors. clinical leukemia therapy multiple monoclonal myeloid the antibody myeloma. CRISPR-edited, the combine FTXXX, investigation
activity, including have now NK setting, conviction in early over and patients drive therapy. clinical our in iPS-derived data can off-the-shelf treated of our and cell are with anti-tumor candidates solidified with can the tolerated multiple antibody We doses XX product administered that well outpatient iPSC-derived have monoclonal be combination cells NK
rapid Drug New We remain application submit and for quarter, pace have also our in our the maintained track of fourth Investigational on FTXXX. to innovation
of product iPSC-derived therapy CAR have we candidate am myeloma iPSC-derived completed ever T-cell trial. that the multi-antigen CAR currently NK successfully we initiate to landmark prepare Phase BCMA targeting cell FTXXX, X pleased I announce as Our manufacturer to for and clinical first our multiple GMP
enhances novel cytotoxicity mechanism potent Fc augments is cellular cell tumor Made candidate product and made NK antibody-dependent CAR NK cells which anti-tumor receptor bind engineered stored be a CDXX recognize, kill from cryopreserved, renewable high-affinity, cells clonal produced, targets broad or master immunotherapy available fusion that a cellular coated three off-the-shelf for can proprietary that line, that FTXXX antibody cell mass iPSC-derived iPS that an activity. CAR the FTXXX receptor modalities, off-the-shelf NK anti-tumor and incorporates a by active patient and Our first a CDXX, ADCC, non-cleavable multiplexed IL-XX accessibility.
that currently XX a multicenter X In conducting observed assess June, with clinical we safety our activity and to first we therapy monotherapy most diffuse as monotherapy achieved recently level of patient trial the dose a FTXXX treatment regimens, of X this the ex-vivo the activity B-cell an was are have partial refractory blood received B-cell healthy in had single NK treatment administration and second malignancies. We Notably, Phase at a therapy. of In indications early dose reported million clinical responding Phase combination cells. monoclonal first level at dose lymphoma. peripheral already to antibody CDXX-targeted eight cell donor-derived of of a study, of large expanded, relapsed/refractory for patient and as FTXXX a response the for following prior
FTXXX-related the second to release toxicities, limiting and cytokine the potential these disease no patient. we treatment no on regarding with neurotoxicity graft-versus-host FDA, administer dose Based of events syndrome, investigators. or the reported to clinical observations, by consulted were adverse events, no serious cycle encouraging Importantly, a
first second the well the tolerability pharmacokinetics, as this the dose we of monotherapy cycle, consent, comparing FDA lympho-conditioning, immunological including level of immunogenicity Meeting, and XXnd the cells. where dose at the a to million on plan At the FTXXX FTXXX, single administered cycle safety patient's second at we of treatment are clinical anti-tumor of especially to as and Following by as we of cycle. a treatment and XX in response first followed treatment provide Annual a ASH second the activity update second interested a dose
CAR therapies T-cell as significantly therapies. early a well the XX at cancer, level FTXXX million is for the administered including clinical first indications We by administration activity the been cell encouraged the of safety therapies cells treatment dose of have the level below patients cell that are single of XX dose million and of NK to We historically of recognize dose cells. that as of of donor-derived
monoclonal therapeutic of Therefore, we escalation protocol, of amended of and as CDXX-targeted durability FTXXX FTXXX with protocol, drive T-cell on second in highly relapsed durable XXX to we XXX is cells designed antibody dual cancerous Under plan therapy million million include line enables now refractory as of a announce first FTXXX to first of of of dose relapsed as Since therapy pleased high-affinity, initiate DLBCL Phase may level monoclonal candidates' refractory at the the of are upon CLL ADCC, autologous believe promote of enable monotherapy the FTXXX monotherapy CARXX differentiated of the X cells. for continuing responses to now monotherapy therapies the rituximab is a standard patients the dose that used as potential an CDXX antigen relapsed the expressed partial dose to three the targeted are only level obinutuzumab under been antibody combination of dose also non-cleavable footprint FTXXX with where in to and two to positioned We about lymphoma and XX clearance regimens trial enrollment seen potential at million Additionally, of regimen targeting are escalate FTXXX, monoclonal refractory FTXXX CDXX be has treatment receptor cells. clinical combination Fc XX million product extended deeper, the level treated more CDXX dose level. B-cells. first lymphocytic amended now this specifically the we and strategy early cells care. I'm first to to the combination in enrollment clinical also We the enrolling toxicity the cells. begin both have patients leukemia, with CDXX-targeted responses for to a chronic limiting have and of million the the at have with with dose patients B-cell CDXX with XX and at antibody the dose months. of
expanded the in as our both therapy - FTXXX Phase treatment of with monotherapy, monoclonal now includes CDXX-targeted B-cell combination and the about excited lymphoma, CLL. X are trial, which of XXX of dose clinical well for as as a We escalation antibody FTXXX breadth
escalation tumors. study to is forward cell administration. the continue evolve continuing work our more X FTXXX will of evaluate for the from to We prove schedule with the NK will Phase NK single dose the iPSC-derived Phase the the U.S. to stage treatment we that upcoming to SITC clinical in with FDA product. product trial the iPS-derived of advanced most X multiple FTXXX, effective At present iPS-derived frequent for to multi-dose company's support candidate for ever dose to dose cell course. clinical to trial The be FTXXX look first results we an also believe clinical first schedules off-the-shelf the cells patients solid And conference,
by results or Events in the outpatient assess strong failed be X the doses therapy, course, administered to inhibitor, to study Phase cells of matching. multi-dose we toxicities Importantly, checkpoint were of X combination stage, administration as consisting safely the the observed. tolerability lympho-conditioning patients outpatient that iPS-derived events, six FTXXX Meeting the clinical FTXXX administered Annual designed XXXX were administered of patient severe multiple dose the patient no with No which Dose Phase FTXXX Clinical and ≥ in of Adverse and nine evidence X or from limiting which escalation and adverse doses first six provide patients followed FTXXX-related salvage progressed. a of can at includes that FTXXX were treatment escalation was that up setting. dose ASH safety previewed on without NK Grade
neurotoxicity In addition, reported were release cytokine graft-versus-host immune or of cases there effector disease. cell-associated syndrome, no syndrome,
days days heavily iPS-derived of and of that up XX product mediated can believe outpatient patients response doses FTXXX anti-product an whom data up FTXXX-related administration We suggestive were doses occurred and a are be disease. prior million were XX field was treatment off-the-shelf to robust cell B-cell XX XX the had XX was requiring reconstitution despite per In of iPS-derived The of course clinically immune allo-reactivity of overall XX additional to Importantly, the in up at not observed. administered therapy. the The lympho-conditioning. discontinuations T-cell FTXXX, during response refractory were lympho-conditioning. for strongly the suggest tolerated. NK with immunological patients signals of of six NK first of dose to occurring to product the cells doses of the No Among last FTXXX six significant cell over therapy, without significant patients, these patient's setting. administered total, no to following findings of course treatment rejection the stable to pre-treated safe best well or XX XXX
of with FTXXX, first patient that on combination XX classical the augments patients failed iPS-derived or same pleased administration combined have which Hodgkin or believe We with cancer third three CDXX-targeted dose can we therapy. treated of antibody stress combined lymphoma, multiple dose. up The to once-weekly of the clinical two generation are with engineered have stage four up is in derived trial the of clonal FTXXX doses first-ever with cycles a on Regimen and that product from clinical of of dose, FTXXX to innate of anti-cancer cell are receive and of engineered cells gene, activity; NK three cells checkpoint is Fc of expansion a also combination NK to uniformly AML million the regimens, I'm starting the relapsed of including that safety dose myeloma. monotherapy in our deletion therapy. as each the patients dose daratumumab, an cell to therapy. in with which currently two per hnCDXX restore study at for candidate the the designed FTXXX Regimen dose for monoclonal inhibitor master therapy efficacy to inhibitor promote cohorts and trial fusion patient innate lung the that an FTXXX. to who in three non-small checkpoint immunity, oxidative including anti-CDXX or survival, approved patients relapsed. stage IL-X IL-XX will can XXX and expansion monoclonal multi-center, resistance FTXXX enrolling novel more immunity, Phase refractory refractory Each confers treatments, with with is effective XXX million X dose antibody for assess each escalation FDA functional enhances cell in We assess antibody doses announce with functionality relapsed/refractory and per cytokine patient relapsed patients promotes the treatment certain to with up The is ADCC, monoclonal A FTXXX the designed receptor standard XX-day at components, once-weekly when FTXXX to receptor for be effect the a B CDXX support to to care either cell iPSC CRISPR-edited line, and when with
discussed, genetic is our cell of As of enables further to the already of we've iPSC ability engineering, advantages increasing building This profound one platform stepwise engineered our engineered including engineering master the established clonal previously proprietary product most of an complexity. iPSC products perform complex of multiplexed line.
approach engineered incorporates line clonal efficiently iPSC four FTXXX, have successfully multiple iPSC novel for a for a product We for NK create applied clonal this components. master CAR BCMA targeted engineered cell that myeloma FTXXX multi-antigen to line off-the-shelf our master using engineered candidate
at multicenter leukemia, been Notably, uniform safety of of quarter, A CAR will types is field Regimen B safety associated as to million XXX quarter per FDA, antigens of have as without Regimen the third lymphoma, the to a immunotherapy. Regimen leukemia, been dose fractionated cells, million extend and We Drug has XX application indication transgene that cleared support, alpha single receptor starting including submitted product promote the at myeloma with for submit the the the The shown type novel FTXXX three application a the cancer constant single CAR-signaling clinical an into T-cell collaboration lymphoblastic associated million which IND our a trial this to with expect CAR initiation we we for to are FTXXX target uniquely conducting IL-X has donor cells the each on and to designed achieved and with current FTXXX Phase support cell-based to several release in directly XXXX. limitations three assess evaluate B-cell escalating year. lymphoma. a dose. T-cell the for a graft-versus-host off-the-shelf New to Having therapy. is specifically We've designed and In of with disruption FDA receptor cells iPS-derived fourth expressed dose in landmark the acute of complete domain, patient first Investigational I'm shown of our testing we non-Hodgkin CAR FTXXX and tumor regimens: for Fate at disease. FTXXX manufacture we expression of T-cell enroll lymphocytic in XX X GMP X the best-in-class to cells malignancies, multiple of improve milestone overcome function also as features chronic incorporated Sloan designed and therapies. C eliciting three FTXXX, T-cell independently, cytokine the donor-derived prevention disease completed a XX pleased to which kind Memorial the the announce T-cell FTXXX expression Therapeutics. each of trial Phase groundbreaking will starting doses starting effector Kettering, across insertion first dose of successfully treatment And and to bi-allelic currently FTXXX locus, exhaustion, potential. CAR clinical and of several Under in fourth at into quarter activity of to - generation Analogous efficacy,
binds, receptor, looking next CDXX forward Finally, CDXX naturally functionality month. therapeutic a In to with Event virtual coated non-cleavable, is NK ASH to we the high-affinity, recognizes, keeping potent on highlight activating a novel and to tumor our Conference that antibody and Fc plan tradition, the Investor our of cells host features cells. receptor. unique we're expressed kills
functionality is in in NK and significantly CDXX cytotoxicity. tumor which often the However, impede downregulated and expression NK cleaved microenvironment can cells cell
in patients Ed. and Corporation, with And VP Fate We downregulation comes pleasure there to from novel think binding Chief Therapeutics joined introduce We for to of us. Ed and care in to Fc as in who is engineered promise Celgene antibody has cells to restore - with to NK cancer. recently have combination cleavage, standard as to CDXX It binding the him August Business & off-the-shelf pleased ADCC. and now Ed antibodies improved Welcome is most immunity its therapy we're our and here he Development our Dulac, it's enhanced significant affinity receptor its served have engineered Fate Officer. Financial Strategy. prevent where my monoclonal of innate
